Drug Trial News

RSS

New findings on STEP HIV vaccine trial

The study is the result of the collaboration between scientists at the Institut de Genetique Moleculaire de Montpellier, Universite Montpellier I & II, Montpellier, France, the Centre Hospitalier Universitaire Vaudois (CHUV) and at the Swiss Vaccine Research Institute, University of Lausanne, Lausanne, Switzerland.

4 Nov 2008

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti- C. difficile antibody combination treatment in patients with C.

4 Nov 2008

Novel leukemia therapy shows promise for high-risk patients

Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.

4 Nov 2008

Study shows how HIV-1 vaccine trial could have enhanced HIV infection

In September 2007, a phase II HIV-1 vaccine trial was abruptly halted when researchers found that the vaccine may have promoted, rather than prevented, HIV infection.

4 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

Halozyme Therapeutics starts phase 2 trial of insulin with rHuPH20 in type 1 diabetes

Halozyme Therapeutics, Inc. today announced it has started a Phase 2 study of proprietary recombinant human hyaluronidase enzyme (rHuPH20) co-formulations with Humulin R (regular insulin human injection) and with Humalog (insulin lispro) in Type 1 diabetic patients.

3 Nov 2008

MedImmune starts phase 1/2a clinical trial for respiratory syncytial virus vaccine

MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

3 Nov 2008

Lithium carbonate to be tested for motor neurone disease

Victims of motor neurone disease (MND) will find hope from British research which has found that lithium carbonate, a cheap off-patent drug, may offer a treatment for the disease.

3 Nov 2008

Cimzia study shows reduction of symptoms and progression of rheumatoid arthritis

UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.

31 Oct 2008

Gleevec holds potential as first drug to successfully treat neurofibromatosis

Researchers at the Indiana University School of Medicine report that the anti-cancer drug Gleevec holds out promise to become the first effective treatment for neurofibromatosis, a genetic disease that has resisted treatments until now.

30 Oct 2008

New signpost to clinical trial expertise

A new comprehensive online resource listing national expertise in the design and conduct of clinical trials is launched today. The UKCRC Registered Clinical Trials Units website provides, for the first time, centralised information on Clinical Trials Units (CTUs) in the UK - including the Bristol Randomised Trials Collaboration (BRTC) at the University of Bristol.

28 Oct 2008

Phenomix starts phase 1a trial of hepatitis C protease inhibitor

Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

28 Oct 2008

New drug combo stops rheumatoid arthritis in its tracks

The trial of a new drug for rheumatoid arthritis (RA) has revealed that an injection once a month could stop the disease progressing.

28 Oct 2008

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Galapagos NV has announced that Nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication.

27 Oct 2008

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.

27 Oct 2008

NanoBio demonstrates new topical approach to treating nail fungus that circumvents problems with current therapy

A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the entire nail plate, according to a study conducted by NanoBio Corporation.

27 Oct 2008

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

26 Oct 2008

Kamada completes final analysis of phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency

Kamada has announced that it has completed the final analysis of its US Phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency.

26 Oct 2008

Leukaemia drug may reverse multiple sclerosis brain damage

Scientists in Britain say a drug which was developed to treat leukaemia may also be a powerful new weapon against multiple sclerosis (MS).

23 Oct 2008

Nymox nears completion of benign prostatic hyperplasia drug trial

Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion.

23 Oct 2008

Drug Trial News

New findings on STEP HIV vaccine trial

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Novel leukemia therapy shows promise for high-risk patients

Study shows how HIV-1 vaccine trial could have enhanced HIV infection

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

Halozyme Therapeutics starts phase 2 trial of insulin with rHuPH20 in type 1 diabetes

MedImmune starts phase 1/2a clinical trial for respiratory syncytial virus vaccine

Lithium carbonate to be tested for motor neurone disease

Cimzia study shows reduction of symptoms and progression of rheumatoid arthritis

Gleevec holds potential as first drug to successfully treat neurofibromatosis

New signpost to clinical trial expertise

Phenomix starts phase 1a trial of hepatitis C protease inhibitor

New drug combo stops rheumatoid arthritis in its tracks

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

NanoBio demonstrates new topical approach to treating nail fungus that circumvents problems with current therapy

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Kamada completes final analysis of phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency

Leukaemia drug may reverse multiple sclerosis brain damage

Nymox nears completion of benign prostatic hyperplasia drug trial

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News